Evidence map›Paper›PMID 41924275›Full record

ArticleFrontiers in immunology2026

New p65 iso5 isoforms as dexamethasone-binding proteins: novel potential therapeutic targets for inflammatory diseases.

Gaetano Spinelli, Giuseppa Biddeci, Gioacchin Iannolo, Paolo Colomba, Giovanni Duro, Emanuela Maria Marsana, Tommaso Silvano Aronica, Francesco Di Blasi

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gaetano SpinelliInstitute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy.
Giuseppa BiddeciInstitute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy.
Gioacchin IannoloDepartment of Research, Istituto di Ricovero e Cura a Carattere Scientifico and Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione (IRCCS), Palermo, Italy.
Paolo ColombaInstitute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy.
Giovanni DuroInstitute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy.
Emanuela Maria MarsanaInstitute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy.
Tommaso Silvano AronicaComplex Operative Unit of Clinical Pathology, Azienda di Rilievo Nazionale ed Alta Specializzazione (ARNAS) Civico Di Cristina e Benfratelli Hospitals, Palermo, Italy.
Francesco Di BlasiInstitute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The transcription factor NF-κB is a central regulator of immune and inflammatory responses whose activity is tightly controlled by IκB proteins and glucocorticoid receptor (GR)-mediated repression. However, the diversity of NF-κB subunit variants and their contribution to glucocorticoid signaling remain incompletely understood. Methods: Human peripheral blood mononuclear cells (PBMCs) exposed to pro- and anti-inflammatory stimuli were analyzed to identify splice variants of the NF-κB subunit p65 iso5. mRNA expression was evaluated under different stimuli. Protein interactions with the synthetic glucocorticoid dexamethasone (Dex) and GR were assessed, together with nuclear translocation dynamics. Functional transcriptional activity was examined using NF-κB and IL-2 responsive promoter assays. Expression profiling was also performed in disease contexts, including COVID-19 and liver cirrhosis. Results: We identified and characterized two previously unrecognized splice variants of p65 iso5, named p65 iso5 Δ6/7 and p65 iso5 Δ10. Their mRNA expression was differentially regulated depending on the stimulus. Both isoforms unexpectedly bound dexamethasone, formed nuclear complexes with Dex-activated GR, and translocated to the nucleus independently of IκBα. Functional assays revealed distinct transcriptional activities on NF-κB and IL-2 responsive promoters, indicating that these isoforms act as noncanonical modulators of glucocorticoid signaling. Expression profiling showed disease-specific regulation, with reciprocal modulation of the two isoforms in COVID-19 and selective upregulation of p65 iso5 Δ6/7 in liver cirrhosis. Discussion: These findings uncover a previously unrecognized layer of NF-κB/GR crosstalk and identify a new class of dexamethasone-binding proteins outside the nuclear receptor superfamily. Our data highlight their glucocorticoid-interacting properties and provide mechanistic insight into the diversity of glucocorticoid responses, with potential implications for inflammation-related pathologies.

Indexed as

COVID-19DexamethasoneInflammationTranscription Factor RelAGlucocorticoidsHumansLeukocytes, MononuclearProtein IsoformsReceptors, GlucocorticoidSARS-CoV-2Signal TransductionDexamethasoneGlucocorticoidsProtein IsoformsReceptors, GlucocorticoidTranscription Factor RelAdexamethasoneglucocorticoid receptorinflammationNF-κBp65 iso5p65 isoforms

Identifiers

PMID41924275
PMCPMC13036746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.